Aether uses its state of the art platform to rapidly engineer enzymes, enabling our customers to manufacture complex and novel products at fractional cost.
Total raised: $49M
Founded date: 2020
Investors 9
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.08.2023 | Series A | $49M | - |
Mentions in press and media 4
| Date | Title | Description |
| 31.10.2023 | TC+ Roundup: What happened to the Adobe-Figma deal? | Good morning, and welcome to Tuesday! It’s been more than a year since Adobe announced that it intended to buy Figma for $20 billion, yet the two companies are still separate entities. As TechCrunch+’s Ron Miller points out, a year is a rea... |
| 16.08.2023 | Aether Raises $49M in Series A Funding | Aether, a Menlo Park, CA-based nanoscale machinery company that can assemble new classes of molecules to create enhanced products, raised $49M in Series A funding. The round was led by Jay Zaveri at Natural Capital and Trevor Zimmerman at U... |
| 12.04.2022 | Aether Biomachines and Allonnia Announce Partnership | Originally published by Business Wire Aether Biomachines and Allonnia Announce Partnership to Engineer Breakthrough Biological Solutions to Degrade PFAS and Other Harmful Environmental Toxins Exclusive partnership to accelerate the remova... |
| - | Aether Bio | “Aether uses its state of the art platform to rapidly engineer enzymes, enabling our customers to manufacture complex and novel products at fractional cost.” |